JP2024534804A5 - - Google Patents

Info

Publication number
JP2024534804A5
JP2024534804A5 JP2024510274A JP2024510274A JP2024534804A5 JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5 JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5
Authority
JP
Japan
Prior art keywords
stereoisomer
solvate
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534804A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2022/012254 external-priority patent/WO2023022497A1/ko
Publication of JP2024534804A publication Critical patent/JP2024534804A/ja
Publication of JP2024534804A5 publication Critical patent/JP2024534804A5/ja
Pending legal-status Critical Current

Links

JP2024510274A 2021-08-17 2022-08-17 Sos1阻害剤及びその使用 Pending JP2024534804A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210108316 2021-08-17
KR10-2021-0108316 2021-08-17
PCT/KR2022/012254 WO2023022497A1 (ko) 2021-08-17 2022-08-17 Sos1 억제제 및 이의 용도

Publications (2)

Publication Number Publication Date
JP2024534804A JP2024534804A (ja) 2024-09-26
JP2024534804A5 true JP2024534804A5 (cg-RX-API-DMAC7.html) 2025-07-25

Family

ID=85239600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510274A Pending JP2024534804A (ja) 2021-08-17 2022-08-17 Sos1阻害剤及びその使用

Country Status (13)

Country Link
US (1) US20240400518A1 (cg-RX-API-DMAC7.html)
EP (1) EP4389738A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534804A (cg-RX-API-DMAC7.html)
KR (1) KR20230026288A (cg-RX-API-DMAC7.html)
CN (1) CN118119600A (cg-RX-API-DMAC7.html)
AU (1) AU2022330732A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229566A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000342A1 (cg-RX-API-DMAC7.html)
IL (1) IL310872A (cg-RX-API-DMAC7.html)
MX (1) MX2024002016A (cg-RX-API-DMAC7.html)
PE (1) PE20240879A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328076A (cg-RX-API-DMAC7.html)
WO (1) WO2023022497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240127910A (ko) * 2023-02-16 2024-08-23 주식회사 카나프테라퓨틱스 Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025163050A1 (en) * 2024-01-31 2025-08-07 Les Laboratoires Servier New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202602869A (zh) * 2024-04-10 2026-01-16 法商施維雅藥廠 新醯胺衍生物、包含其之醫藥組合物及其作為sos1抑制劑之用途
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026038916A1 (ko) * 2024-08-14 2026-02-19 (주) 사이러스테라퓨틱스 Sos1 억제 활성을 갖는 신규 화합물
CN119431234A (zh) * 2024-08-19 2025-02-14 中国药科大学 一种苄胺甲酰类化合物及其制备方法与应用
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
JP5572725B2 (ja) * 2010-03-10 2014-08-13 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎の処置のための化合物
CN102558147B (zh) * 2010-12-23 2014-09-17 江苏先声药物研究有限公司 化合物、制备方法及应用
AR086113A1 (es) * 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
MX2014012991A (es) * 2012-04-24 2015-08-14 Chugai Pharmaceutical Co Ltd Derivado de benzamida.
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014205594A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
EP3061747B1 (en) * 2013-10-25 2021-04-07 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
PL3728254T3 (pl) * 2017-12-21 2023-06-12 Boehringer Ingelheim International Gmbh Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
WO2021028645A1 (en) * 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4472974A4 (en) * 2022-02-04 2026-03-25 Schroedinger Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP7485810B2 (ja) 癌を処置する方法
JP3397320B2 (ja) 縮合イミダゾリウム誘導体
KR102381295B1 (ko) {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도
AU2008267048B2 (en) Azapeptide derivatives
JP2023552610A5 (cg-RX-API-DMAC7.html)
TW202015698A (zh) Tlr7/tlr8抑制劑之晶型
RU2011121876A (ru) Пиразолопиримидиновые соединения-ингибиторы jak и способы
CN105473573B (zh) 用作激酶抑制剂的咔唑甲酰胺化合物
CN112135827A (zh) 盐、晶型及其制备方法
AU2007220419A1 (en) Selective androgen receptor modulators
JP2004516314A5 (cg-RX-API-DMAC7.html)
JP2021522262A5 (cg-RX-API-DMAC7.html)
SG11202110683WA (en) Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
WO2017120124A1 (en) Azetidine modulators of the sphingosine 1-phosphate receptor
CN105026362B (zh) 双环化合物
CN108778288A (zh) 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂
JP2021536505A5 (cg-RX-API-DMAC7.html)
JP2025511277A5 (cg-RX-API-DMAC7.html)
CN121889382A (zh) Prmt5抑制剂及其制备方法
JP2025502712A5 (cg-RX-API-DMAC7.html)
JP2022549601A5 (cg-RX-API-DMAC7.html)
JP2025502497A (ja) 3-[(ベンゾ[d][1,3]ジオキソラン-4-イル)オキシ]プロピルアミン塩酸塩およびその光学異性体、結晶、ならびに調製方法
JP2023547346A5 (cg-RX-API-DMAC7.html)
JP2021514347A (ja) 抗rsv活性を有するシクロアルキル置換ピラゾロピリミジン
KR20040034804A (ko) 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물